Coronary Artery Disease

Norvasc study reports fewer major CV events in coronary artery disease patients

Published in Clinical Trials Week, December 6th, 2004

Pfizer Inc said that patients with coronary artery disease who took its blood pressure lowering medicine Norvasc (amlodipine besylate) had 31% fewer major cardiovascular events compared to patients who received standard care.

The results were published in the current issue of the Journal of the American Medical Association.

In the 2-year Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis (CAMELOT) trial, 1,997 patients with coronary artery disease and normal or well-controlled hypertension received either Norvasc, the ace-inhibitor enalapril (Vasotec) or placebo to compare the medicines' effectiveness in reducing major...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2004-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry